--- title: "Ligand Pharma Completes Major Convertible Notes Financing Transaction" type: "News" locale: "en" url: "https://longbridge.com/en/news/290882942.md" description: "Ligand Pharma completed a $700 million private offering of 0.00% convertible senior notes due 2031, netting ~$678.2 million. Proceeds were used for hedge transactions and share repurchases. The company maintains a 'Buy' rating with a $330 target, while AI analyst Spark rates it 'Outperform' based on strong profitability, despite valuation concerns." datetime: "2026-06-25T21:35:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290882942.md) - [en](https://longbridge.com/en/news/290882942.md) - [zh-HK](https://longbridge.com/zh-HK/news/290882942.md) generator: "portal-rs" --- # Ligand Pharma Completes Major Convertible Notes Financing Transaction ### TipRanks' Prime Week Sale - 70% Off - Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. - Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Ligand Pharma ( (LGND) ) just unveiled an update. On June 25, 2026, Ligand Pharmaceuticals closed a previously announced $700 million private offering of 0.00% convertible senior notes due 2031, including the full exercise of a $75 million overallotment option, issuing senior unsecured securities convertible into common stock at an initial price of about $334.27 per share, a 27.5% premium to the June 22, 2026 Nasdaq close. The company realized approximately $678.2 million in net proceeds, using about $72.9 million to purchase convertible note hedge transactions and about $60 million, alongside cash on hand, to repurchase 228,859 shares at $262.17 per share, while also entering related warrant deals that may introduce dilution above a $524.34 strike price, collectively enhancing financial flexibility but adding potential future equity overhang depending on stock performance and conversion dynamics. The notes, which bear no regular interest and do not accrete, mature on September 15, 2031 and can be converted under specified stock price and trading conditions before June 15, 2031, and at any time thereafter until shortly before maturity, with Ligand settling principal in cash and any excess value in cash, stock or a combination. Ligand may redeem the notes for cash from September 21, 2029 if its share price trades at least 130% of the conversion price for a defined period, while investors receive standard downside protections including a fundamental change put at par and detailed default and covenant provisions that tie acceleration to payment failures, reporting breaches, large cross-defaults and bankruptcy events, establishing a typical convertible structure that balances low-cost financing for the company with contingent dilution and event protections for noteholders. The most recent analyst rating on (LGND) stock is a Buy with a $330.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page. **Spark’s Take on LGND Stock** According to Spark, TipRanks’ AI Analyst, LGND is a Outperform. Score is driven primarily by strong TTM profitability/cash generation and a constructive earnings outlook tied to guidance and portfolio-scaling catalysts (including XOMA). Offsetting factors are premium valuation and technically overbought conditions, plus financing/legal-related event risk. To see Spark’s full report on LGND stock, click here. **More about Ligand Pharma** Ligand Pharmaceuticals Incorporated is a U.S.-based biopharmaceutical company focused on developing and acquiring pharmaceutical royalties and drug discovery technologies. The company targets revenue streams from partnered medicines and royalty-bearing assets, positioning itself as a capital-light player within the life sciences and pharmaceutical royalty markets. **Average Trading Volume:** 274,814 **Technical Sentiment Signal:** Buy **Current Market Cap:** $5.6B ### Related Stocks - [LGND.US](https://longbridge.com/en/quote/LGND.US.md) - [XOMA.US](https://longbridge.com/en/quote/XOMA.US.md) - [XOMAP.US](https://longbridge.com/en/quote/XOMAP.US.md) - [XOMAO.US](https://longbridge.com/en/quote/XOMAO.US.md) ## Related News & Research - [Is Ligand Pharmaceuticals (LGND) Undervalued On Its Conference Appearance?](https://longbridge.com/en/news/297426603.md) - [Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance](https://longbridge.com/en/news/297061481.md) - [$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296632631.md) - [LGND: XOMA acquisition doubled the portfolio and set the stage for accelerated, diversified growth](https://longbridge.com/en/news/297069508.md) - [Ranger Investment Management L.P. Acquires Shares of 257,596 Ligand Pharmaceuticals Incorporated $LGND](https://longbridge.com/en/news/296772770.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**